With the creation of a novel domestic vaccine candidate named AdFalciVax, India has made significant progress in the fight against malaria. The Indian Council of Medical Research (ICMR), in collaboration with the Department of Biotechnology’s National Institute of Immunology (DBT-NII), is developing this vaccine through its institutes, RMRC Bhubaneswar and the National Institute of Malaria Research (NIMR).
The two main stages of Plasmodium falciparum, the parasite that causes the most deadly type of malaria, are the focus of the novel malaria vaccine AdFalciVax. Since AdFalciVax targets both the stage of the parasite life cycle that causes human illness and the stage that mosquitoes transmit, it offers better and more durable protection than the majority of current vaccines, which only target one stage.
The vaccine has performed exceptionally well in preliminary laboratory tests. Researchers think it could have a number of advantages over existing vaccinations including RTS, S/AS01, and R21/Matrix-M. These include enhanced long-term immunity, increased protection, and a decreased likelihood of the parasite evading the immune response.
Additionally, the vaccine is stable at room temperature for more than nine months, which facilitates storage and transportation, particularly in tropical areas. Alum, which is frequently used as an adjuvant in vaccinations, is another inexpensive chemical it employs.
At the moment, the vaccine is in the preclinical phase. The vaccine may not be available for general use for almost seven years, if all goes according to plan. Clinical testing, regulatory clearances, and manufacturing under stringent safety requirements are all part of the development timeframe.
AdFalciVax’s utilization of “Lactococcus lactis,” a safe and well-known bacterium utilized in vaccine production, is one of its main advances. Because of its design, it can both prevent people from becoming ill and stop malaria from spreading throughout communities.
Under non-exclusive agreements, the ICMR intends to make the vaccine technology available to other companies and organizations. This implies that several businesses can collaborate on the vaccine’s development, enabling it to reach more people more quickly after approval. In keeping with the government’s “Make in India” campaign, AdFalciVax is being developed exclusively in India.
Disclaimer:
The information contained in this article is for educational and informational purposes only and is not intended as a health advice. We would ask you to consult a qualified professional or medical expert to gain additional knowledge before you choose to consume any product or perform any exercise.
